Evidence map›Paper›PMID 30931679›Full record

ArticleRenal failure2019

Intermedin protects HUVECs from ischemia reperfusion injury via Wnt/β-catenin signaling pathway.

Yanhong Wang, Zhijing Wu, Jihua Tian, Yang Mi, Xiaojun Ren, Jing Kang, Wan Zhang, Xiaoshuang Zhou, Guiqin Wang, Rongshan Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. IntermedinJournal of inflammation research · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yanhong Wanga Department of Microbiology and Immunology , Shanxi Medical University , Taiyuan , China.
Zhijing Wua Department of Microbiology and Immunology , Shanxi Medical University , Taiyuan , China.
Jihua Tiana Department of Microbiology and Immunology , Shanxi Medical University , Taiyuan , China.
Yang Mic Department of Urology , First Hospital of Shanxi Medical University , Taiyuan , China.
Xiaojun Rend Department of Nephrology , Shanxi Dayi Hospital of Shanxi Medical University , Taiyuan , China.
Jing Kanga Department of Microbiology and Immunology , Shanxi Medical University , Taiyuan , China.
Wan Zhangd Department of Nephrology , Shanxi Dayi Hospital of Shanxi Medical University , Taiyuan , China.
Xiaoshuang Zhoub Department of Nephrology , The Affiliated People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Shanxi Kidney Disease Institute , Taiyuan , China.
Guiqin Wanga Department of Microbiology and Immunology , Shanxi Medical University , Taiyuan , China.
Rongshan Lib Department of Nephrology , The Affiliated People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Shanxi Kidney Disease Institute , Taiyuan , China.
Shanxi Medical University · CNShaoxing People's Hospital · CNShanxi Dayi Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intermedin (IMD) is a member of the calcitonin gene-related peptide (CGRP) superfamily and a pro-angiogenic factor. In the present study, we identified activation of the Wnt/β-catenin signaling pathway by IMD. Adding CoCl

Indexed as

Neovascularization, Physiologicbeta CateninCell LineCobaltDown-RegulationHumansHuman Umbilical Vein Endothelial CellsImidesPeptide HormonesQuinolinesReceptor Activity-Modifying Protein 2Reperfusion InjuryUp-RegulationVascular Endothelial Growth Factor AWnt Signaling PathwayADM2 protein, humanbeta CateninCobaltcobaltous chlorideCTNNB1 protein, humanImidesIWR-1 compoundPeptide HormonesQuinolinesRAMP2 protein, humanReceptor Activity-Modifying Protein 2Vascular Endothelial Growth Factor AVEGFA protein, humanangiogenesishypoxia/reoxygenationIMDWnt/β-catenin signaling

Identifiers

PMID30931679
PMCPMC6450471
OpenAlexW2927338548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.